2026-08-10 · BOTH · TopGLP1Providers Data Desk
Stopping a GLP-1 subscription: the complete off-ramp
Stopping payment on a GLP-1 program triggers three separate endings that people routinely conflate: the medication shipments stop on your subscription terms; any membership keeps billing until separately cancelled ($25–$145/month across this index); and the prescription itself expires on its own clock, which is what makes restarting later a new intake rather than a resumed one. Knowing which lever ends which charge is the difference between a clean exit and three months of zombie billing.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The billing off-ramp, program type by program type. Single-price programs (NexLife↗, Yucca, Henry and the rest of the no-membership list) are the clean case: cancel the subscription per the published terms and billing ends with it. Membership programs require two cancellations — medication and platform — and the platform fee is the one that survives forgetfulness: Mochi’s $79, Eden’s $99, LifeMD↗’s $149, Ro’s $145 all recur independently of whether medication ships. Prepaid terms are the third case: stopping mid-term converts the refund clause from fine print into the entire relationship — prorated at the better programs, forfeit at others — which is why the clause belongs in writing before the term begins. Whatever the structure: cancel in the channel the terms specify, screenshot the confirmation, and audit the next two statements.
The clinical half, stated carefully. This site prices programs; it does not advise stopping, starting, or pausing medication — that conversation belongs with your prescriber, and it is worth having before the billing decision rather than after, because the published evidence on GLP-1 discontinuation is consistent on one point: in trial extensions, participants who stopped regained a substantial share of lost weight over the following year. A planned conversation about tapering, maintenance dosing, or transition strategy is a different situation from a lapsed card, and only one of them was chosen. If cost is the reason for stopping, say so to the prescriber and to yourself in the same breath as reading the next paragraph — because the price of staying has been falling.
The restart math, at 2026 prices. Restarting after a gap generally means a new intake, a new prescription, and — clinically — often a re-titration from a lower dose, which has a pricing consequence: on dose-tiered programs a restart re-enters at the cheaper starter rungs, while on dose-flat programs ($215 at every dose at the current floor) the restart price equals the price you left. It also means re-shopping a market that moves: the verified tirzepatide floor is $215 and the brand maintenance benchmark $449 today, both lower than a year ago, and a returning buyer should treat the current rankings and calculator as a fresh decision rather than a resumed one. The cheapest structure for anyone who anticipates pausing is the one with nothing to strand: month-to-month billing, no membership, no prepaid balance — the exact filter behind the no-commitment list.
Discontinuation effects summarized from published trial extensions as general information; individual decisions about stopping or pausing medication belong with a licensed clinician.